Autoimmune disease and/or autoantibodies have been reported in mood disorder patients. We screened for autoantibodies to glutamic acid decarboxylase (GAD65), thyroid peroxidase (TPO), gastric H+/K+ ATPase (ATP4B), and Ro52 in a psychiatric patient cohort. A 24-year-old woman with major depressive disorder (MDD) with reduced psychomotor activity was identified with unusually high serum GAD65 and Ro52 autoantibody titers. Anti-GAD65 and anti-Ro52 autoantibodies were also elevated in the CSF from this patient. Longitudinal examination revealed a four-fold increase in anti-GAD65 serum antibody titers which correlated with exacerbation of psychomotor symptomatology. These results suggest the possibility that CNS autoimmunity may be responsible for the psychomotor impairment in this MDD patient.
Introduction
The relationship between the immune system and the pathogenesis of mood disorder has been the focus of numerous studies. Several groups observed an increased prevalence of autoimmune disease and/ or autoantibodies in patients with bipolar disorder, including autoimmune thyroiditis and autoimmune atrophic gastritis (Kupka et al., 2002) . Padmos et al. (2004) reported significant titers of autoantibodies to glutamic acid decarboxylase-65 (GAD65), thyroid peroxidase (TPO) and gastric H+/K+ ATPase (ATP4B) in a bipolar patient cohort. Luciferase Immunoprecipitation Systems (LIPS) is a highly sensitive and specific assay which harnesses light-emitting recombinant antigen fusion proteins to quantitatively measure patient antibody titers (Burbelo et al., 2009a) . Previously, LIPS has been shown to be as good as, or superior to existing immunoassays in the detection of antibodies in several autoimmune conditions, including Sjögren's Syndrome (Burbelo et al., 2009b) , type I diabetes (Burbelo et al., 2010) and Stiff Person Syndrome (SPS) (Burbelo et al., 2008a) . For detection of anti-GAD65 autoantibodies, LIPS demonstrated equal diagnostic performance to the established radiobinding assay for the diagnosis of type I diabetes (Burbelo et al., 2010) . Using LIPS, we screened a cohort of 58 psychiatric patients and 44 healthy controls for autoantibodies to TPO, ATP4B, Ro52 and GAD65.
Materials and methods

Patient sera and CSF
Patients were evaluated under Institutional Review Board-approved protocols at the National Institute of Mental Health (Bethesda, MD), were medically healthy and had been unmedicated for at least three weeks prior to blood sampling. The cohort included 42 major depressive disorder patients (21 currently-depressed and 21 in full remission; DSM-IV criteria), 16 depressed bipolar disorder patients, and 44 healthy controls. The controls were recruited from the same community as the patients using advertisements in local media. All patients and controls underwent an identical screening process, which included both structured and unstructured psychiatric interviews, a medical history and physical examination conducted by a physician, electrocardiogram and a neuromorphological MRI scan to rule out gross brain pathology. Other clinical and laboratory tests were also performed, including complete blood count, electrolytes, liver and thyroid functions, urine analysis, pregnancy testing (for females) and HIV plus hepatitis viral screening. Sera and CSF were kept at −80°C, thawed, aliquoted, and then stored at 4°C prior to measurement.
